Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 7/20 | 0.39 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17324236 | 0.91 | CYP19A1 (0.38) | CYP19A1MIFPOLBMEN1PABPC1 | |
| SCHEMBL22854013 | 0.87 | CYP19A1 (0.39) | CYP19A1MIFPOLBMEN1PABPC1 | |
| SCHEMBL26501075 | 0.83 | CYP19A1 (0.33) | CYP19A1MIFPOLBMEN1KMT2A | |
| SCHEMBL26501074 | 0.83 | CYP19A1 (0.33) | CYP19A1MIFPOLBMEN1KMT2A | |
| SCHEMBL25735013 | 0.82 | CYP19A1 (0.37) | CYP19A1MIFPOLBMEN1PABPC1 | |
| SCHEMBL16674191 | 0.81 | CYP1A2 (0.41) | CYP19A1POLBACHE | |
| SCHEMBL14434943 | 0.81 | L3MBTL1 (0.49) | CYP19A1POLBHDAC1 | |
| SCHEMBL14434944 | 0.80 | CYP19A1 (0.42) | CYP19A1POLB | |
| SCHEMBL20362415 | 0.78 | EPHX2 (0.47) | CYP19A1HDAC1 | |
| SCHEMBL19296369 | 0.78 | FOLH1 (0.47) | HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159554-A1 | COMPOUND WITH ANTICANCER ACTIVITY | KYOWA KIRIN CO., LTD. (JP) | 2023-05-25 | — | — | US | disclosed |
| US-11254705-B2 | Cyclic peptide analogs and conjugates thereof | SIRENAS LLC (US) | 2022-02-22 | — | — | US | disclosed |
| US-20190211060-A1 | CYCLIC PEPTIDE ANALOGS AND CONJUGATES THEREOF | SIRENAS LLC (US) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190211060-A1 | CYCLIC PEPTIDE ANALOGS AND CONJUGATES THEREOF | VIP, NGLY1, GRPR | CYP19A1 1525/4885MIF 1131/4885POLB 3318/4885 |
| US-11254705-B2 | Cyclic peptide analogs and conjugates thereof | VIP, NGLY1, GRPR | CYP19A1 1525/4885MIF 1131/4885POLB 3318/4885 |
| US-20230159554-A1 | COMPOUND WITH ANTICANCER ACTIVITY | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 | CYP19A1 1769/4885MIF 2029/4885POLB 4039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.